Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-240: Pembrolizumab vs Best Supportive Care as Second-Line Therapy in Advanced Hepatocellular Carcinoma
2015-004567-36Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Pembrolizumab with Best Supportive Care (2 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2015-004567-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004567-36.